Jesse Schulman

Cooley advised Abivax, a clinical-stage biotech company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.

Cooley advised the underwriters in Vistagen Therapeutics’ $100 million follow-on offering of common stock, pre-funded warrants, and two tranches of common stock warrants, with Jefferies, Stifel and William Blair acting as lead book-running managers. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders. Partners Denny Won, Charlie Kim and Courtney Tygesson led the Cooley team.

Cooley advised TPB Acquisition Corporation I, a special purpose acquisition company sponsored by The Production Board, in its business combination agreement that will result in Lavoro Limited, a leading agricultural inputs retailer in Latin America, becoming a US publicly listed company with an implied initial enterprise value of approximately $1.2 billion.

Cooley advised World View, a leader in stratospheric exploration and flight, on its definitive business combination agreement with publicly traded special purpose acquisition company Leo Holdings Corp. II. The transaction will result in World View becoming a publicly listed company. Partners Alex Kassai, Milson Yu and Miguel Vega led the Cooley team advising World View.

Cooley advised the underwriters in Aura Biosciences’ $86.7 million follow-on offering. SVB Securities, Cowen and Evercore ISI acted as joint bookrunning managers for the offering. Aura is a clinical-stage biotechnology company that is leveraging its novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. Partners Rich Segal, Div Gupta and Daniel Goldberg led the Cooley team.